Rosenzwajg et al., in 2018, assessed the use of low dose of IL-2 in 11 types of rheumatological diseases and reported the universal safety, biological efficacy and possible clinical efficacy of low dose of IL-2 across a group of very heterogeneous diseases including, psoriasis, rheumatoid arthritis (RA), ankylosing spondylitis (AS), SLE, Behçet’s disease, granulomatosis with polyangiitis, Takayasu’s disease, Crohn’s disease (CD), ulcerative colitis (UC), autoimmune hepatitis and sclerosing cholangitis [43, 44]. This evidence concerns the gene IL2 and Crohn disease.